Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.80 |
| ▸ | EGFR | P00533 | 9/20 | 0.79 |
| ▸ | ITK | Q08881 | 7/20 | 0.79 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.60 |
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | CDK9 | P50750 | 2/20 | 0.60 |
| ▸ | BTK | Q06187 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
| ▸ | TEC | P42680 | 1/20 | 0.60 |
| ▸ | TXK | P42681 | 1/20 | 0.60 |
| ▸ | BMX | P51813 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | CD69 | Q07108 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656511 | 0.90 | SYK (1.00) | SYKEGFRITK | |
| SCHEMBL12519538 | 0.89 | EGFR (1.00) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL29722231 | 0.89 | EGFR (1.00) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL655281 | 0.87 | EGFR (0.69) | SYKEGFRITKCCNT1CCNE1 | |
| SCHEMBL655884 | 0.85 | SYK (0.85) | SYKEGFRITKBTK | |
| SCHEMBL653838 | 0.85 | SYK (1.00) | SYKEGFRITK | |
| SCHEMBL20216164 | 0.84 | EGFR (0.83) | SYKEGFRITKBTK | |
| SCHEMBL20216167 | 0.83 | EGFR (0.83) | SYKEGFRITKBTK | |
| SCHEMBL15814036 | 0.82 | EGFR (0.88) | EGFRITKBTKJAK2LYN | |
| SCHEMBL656819 | 0.82 | SYK (0.79) | SYKEGFRITKBTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SYK 610/4885EGFR 460/4885ITK 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.